Paclitaxel can also be encapsulated in alternative polymeric nanomaterials, such as Abraxane (albumin-bound paclitaxel) and pH-sensitive materials, which have demonstrated efficacy in recurrent/metastatic HNSCC by markedly inhibiting the PD-1/PD-L1 IC and decreasing TIM3+ CD8+ CTLs [105,107]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.